Peripheral Blood Markers Identify Risk of Immune‐Related Toxicity in Advanced Non‐Small Cell Lung Cancer Treated with Immune‐Checkpoint Inhibitors

BACKGROUND. Immune‐checkpoint inhibitors (ICIs) are now standard of care for advanced non‐small cell lung cancer (NSCLC). Unfortunately, many patients experience immune‐related adverse events (irAEs), which are usually mild and reversible, but they require timely management and may be life threateni...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncologist
Main Authors: Pavan, Alberto, Calvetti, Lorenzo, Dal Maso, Alessandro, Attili, Ilaria, Del Bianco, Paola, Pasello, Giulia, Guarneri, Valentina, Aprile, Giuseppe, Conte, PierFranco, Bonanno, Laura
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley & Sons, Inc. 2019
Assuntos:
Lung Cancer
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6693718/
https://ncbi.nlm.nih.gov/pubmed/31015312
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2018-0563
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados